Edwards Lifesciences FY2025 publishes annual report; sales from continuing operations rise to $6.1 billion

Reuters03-27

Edwards Lifesciences FY2025 publishes annual report; sales from continuing operations rise to $6.1 billion

Edwards reported progress across its structural heart portfolio, citing expanded indications for its SAPIEN 3 transcatheter aortic valve platform, including FDA approval for treating asymptomatic severe aortic stenosis based on the EARLY TAVR trial.
Transcatheter mitral and tricuspid therapies were updated with U.S. and European approvals for the SAPIEN M3 mitral valve replacement system, alongside broader adoption of the PASCAL repair platform and the EVOQUE tricuspid replacement system.
Surgical portfolio updates included additional durability evidence for RESILIA tissue and a 2025 European launch of the KONECT RESILIA aortic valved conduit.
Research and development spending was described as exceeding USD 1.0 billion, with investment priorities spanning TAVR, mitral and tricuspid therapies, and surgical platforms, plus programs in heart failure management and aortic regurgitation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622583894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 05:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622583894","market":"nz","top_or_hot":-1,"title":"Edwards Lifesciences FY2025 publishes annual report; sales from continuing operations rise to $6.1 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Edwards Lifesciences FY2025 publishes annual report; sales from continuing operations rise to $6.1 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Edwards reported progress across its structural heart portfolio, citing expanded indications for its SAPIEN 3 transcatheter aortic valve platform, including FDA approval for treating asymptomatic severe aortic stenosis based on the EARLY TAVR trial.\n        </li>\n<li>\n          Transcatheter mitral and tricuspid therapies were updated with U.S. and European approvals for the SAPIEN M3 mitral valve replacement system, alongside broader adoption of the PASCAL repair platform and the EVOQUE tricuspid replacement system.\n        </li>\n<li>\n          Surgical portfolio updates included additional durability evidence for RESILIA tissue and a 2025 European launch of the KONECT RESILIA aortic valved conduit.\n        </li>\n<li>\n          Research and development spending was described as exceeding USD 1.0 billion, with investment priorities spanning TAVR, mitral and tricuspid therapies, and surgical platforms, plus programs in heart failure management and aortic regurgitation.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edwards Lifesciences FY2025 publishes annual report; sales from continuing operations rise to $6.1 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdwards Lifesciences FY2025 publishes annual report; sales from continuing operations rise to $6.1 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 05:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Edwards Lifesciences FY2025 publishes annual report; sales from continuing operations rise to $6.1 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Edwards reported progress across its structural heart portfolio, citing expanded indications for its SAPIEN 3 transcatheter aortic valve platform, including FDA approval for treating asymptomatic severe aortic stenosis based on the EARLY TAVR trial.\n        </li>\n<li>\n          Transcatheter mitral and tricuspid therapies were updated with U.S. and European approvals for the SAPIEN M3 mitral valve replacement system, alongside broader adoption of the PASCAL repair platform and the EVOQUE tricuspid replacement system.\n        </li>\n<li>\n          Surgical portfolio updates included additional durability evidence for RESILIA tissue and a 2025 European launch of the KONECT RESILIA aortic valved conduit.\n        </li>\n<li>\n          Research and development spending was described as exceeding USD 1.0 billion, with investment priorities spanning TAVR, mitral and tricuspid therapies, and surgical platforms, plus programs in heart failure management and aortic regurgitation.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFXG0V08.USD","symbol_name":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3Rp014:1","article_id":"2622583894","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622583894","pubTimestamp":1774561248,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Edwards reported progress across its structural heart portfolio, citing expanded indications for its SAPIEN 3 transcatheter aortic valve platform, including FDA approval for treating asymptomatic severe aortic stenosis based on the EARLY TAVR trial.Transcatheter mitral and tricuspid therapies were updated with U.S. and European approvals for the SAPIEN M3 mitral valve replacement system, alongside broader adoption of the PASCAL repair platform and the EVOQUE tricuspid replacement system.Surgical portfolio updates included additional durability evidence for RESILIA tissue and a 2025 European launch of the KONECT RESILIA aortic valved conduit.Research and development spending was described as exceeding USD 1.0 billion, with investment priorities spanning TAVR, mitral and tricuspid therapies, and surgical platforms, plus programs in heart failure management and aortic regurgitation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","BK4082":"医疗保健设备","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","BK4567":"ESG概念","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","EW":"爱德华兹","BK4504":"桥水持仓","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999001176.USD":"United Global Healthcare Acc USD"},"translate_title":"爱德华兹生命科学2025财年发布年度报告；持续经营业务销售额升至61亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":0.9},"content_text":"Edwards Lifesciences FY2025 publishes annual report; sales from continuing operations rise to $6.1 billion\n    \n\n\n          Edwards reported progress across its structural heart portfolio, citing expanded indications for its SAPIEN 3 transcatheter aortic valve platform, including FDA approval for treating asymptomatic severe aortic stenosis based on the EARLY TAVR trial.\n        \n\n          Transcatheter mitral and tricuspid therapies were updated with U.S. and European approvals for the SAPIEN M3 mitral valve replacement system, alongside broader adoption of the PASCAL repair platform and the EVOQUE tricuspid replacement system.\n        \n\n          Surgical portfolio updates included additional durability evidence for RESILIA tissue and a 2025 European launch of the KONECT RESILIA aortic valved conduit.\n        \n\n          Research and development spending was described as exceeding USD 1.0 billion, with investment priorities spanning TAVR, mitral and tricuspid therapies, and surgical platforms, plus programs in heart failure management and aortic regurgitation.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622583894","isCrawlerRequest":true}